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Abstract: 
Millions of people die each year from infectious diseases. This is partly due to the 
difficulty of transporting temperature dependent vaccines through what is called the cold chain 
in developing countries. I hypothesize that we can increase vaccine accessibility by finding cost 
effective alternatives to vaccine production and by eliminating the cold chain through vaccine 
stabilizers. The gold standard in purification of influenza virus is by means of 
ultracentrifugation . Although effective, this process is very expensive and thus impractical for 
developing countries . I hypothesize that column chromatography can be a cost efficient 
alternative that is as effective as ultracentrifugation . The purification ability of column 
chromatography was tested by comparing two different chromatography resins. The Capto Q 
resin separates proteins on the basis of protein charge . The Capto 700 resin separates proteins 
on the basis of both size and charge. It was found that while protein separation occurred, more 
research will be required to assure full viral protein purification. 
It is hypothesized that vaccine stabilizers can be used to eliminate the cold chain. The 
effect of the gelatin on inactivated influenza virus vaccines was evaluated using hemagglutinin (HA) 
assays and neuraminidase (NA) assays. The assays evaluate viral protein activity in samples exposed 
to elevated temperatures for set periods of time (1 min, 5 min, 10 min, 20 min, 40 min, 60 min, 120 
min, 240 min, 300 min, and 360 min). Elevated temperatures (45, 52, and 60 degrees Celsius) 
facilitated an accelerated stability test, which simulates extended effects of time on vaccines. In 
addition to testing different temperatures, the following concentrations of collagen were used as 
percent by total volume: 0.3%, 1%, 3%, and 10%. These were tested for optimizing the stabilization 
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of the vaccine . The results of the neuraminidase assay show that 3% collagen significantly increased 
the stability of the vaccine by approximately 10,000 fold . 
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Introduction 
1.1 Background 
It is estimated that 17 million people die each year from infectious diseases (Chen et al., 
2011) . This accounts for more than half of the deaths found in the poorest of developing 
countries (Yager et al., 2006). While our medical technology is advancing, pandemics such as 
HIV and Ebola are still rampaging through the developing world killing millions of people each 
year. Many infectious agents such as anthrax and small pox pose threats that could be used as 
weapons in bioterrorism. While antibiotics are used as a means of rescue, vaccines have been 
considered one of the greatest medical advancements in preventing such diseases (Kumru et 
al., 2014). While the need for vaccines is crucial, many do not have access to them . 
The lack of vaccine accessibility is partially the result of 1) the cost of manufacturing, 
and 2) the insufficiency of the transportation cold chain. I hypothesize that vaccine accessibility 
could be increased by addressing either of these two problems. By finding cost alternatives to 
manufacturing, such as column chromatography, developing nations could find ways to 
manufacture vaccines in their own country . If vaccines are manufactured on site , one could 
eliminate the costs of transportation. In addressing the insufficiency of the cold chain, I 
hypothesize that gelatin could be used as a vaccine stabilizer thus eliminating the need for a 
cold chain. 
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1.2 Costs of Manufacturing 
A vital step in vaccine production is the purification of the virus in the vaccine. Normally 
this purification is done through ultracentrifugation. While effective, ultracentrifugation is 
extremely expensive making it impractical for developing countries. Column Chromatography 
is a purification alternative that is cost efficient. It is hypothesized that column 
chromatography may be as effective as ultracentrifugation and could be utilized in developing 
countries for vaccine production. 
We used the influenza A/NWS/33 (HlNl) virus to test the purification ability of column 
chromatography. Madin Darby Canine Kidney (MDCK) cells were infected with virus, the virus 
was then inactivated by means of Binary Ethyleneimine (BEi). To compare the purification 
ability of column chromatography two different chromatography resins were used: Capto Q and 
Capto 700. 
Capto Q is a resin that separates 
proteins on the basis of charge. This is 
done by anion exchange. The Capto Q 
resin uses a quaternary Amine group 
that has a positive charge. This allows 
proteins with a negative charge to bind 
to the column allowing them to be 
separated from the rest of the solution 
flowing through the column. 
Figure 1: Artistic portrayal of the Capto 700 resin. 
Picture displays the ligand-activated core, as well as 
the outer membrane containing microscopic pores. 
Small proteins (in purple and yellow) are able to bind 
to the core while contaminants (shown in red) cannot 
penetrate the outer shell 
http://wolfson.huji.ac.il/purification/PDF/HCIC/GE CaptoCore700 
DataFile.pdf 
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The second resin used was Capto 700 (Figure 1). This resin separates by size as well as 
charge. It has the ability to separate both size and charge because the resin is composed of 
beads that have a ligand-activated core and an outer layer that is composed of little 
microscopic pores. The outer shell prevents large molecules from entering and binding to the 
hydrophobic and positively charged ligands . Because both resins separate on the basis of 
charge, elution buffers with a gradient of increasing salt concentrations were used for elution of 
bound proteins. 
1.3 Insufficiency of the Transportation Cold Chain 
While vaccines are effective in preventing the spread of fatal diseases, they are 
rendered useless if exposed to conditions outside of the optimal range. The World Health 
Organization (WHO, 2006) has said that the only environmental factor to affect characteristics 
of all vaccines is temperature . This is why vaccine transportation relies so heavily on the cold 
chain. 
Zhang et al. (2012) defines the cold chain as the distribution network that strives to 
keeps vaccines within the optimal temperature range during transport, storage, and handling. 
This not only means keeping the vaccine from getting too warm , but also from freezing . 
Vaccines contain molecules called adjuvants that increase the potency of the vaccine. Adjuvants 
such as aluminum , however, are inactivated if frozen (Kumru et al., 2014). Accidental exposure 
of vaccines to freezing temperatures during the length of the cold chain occurs in over 75% of 
all shipments (Kumru et al., 2014) . 
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The process of the cold chain can often be lengthy . Most vaccine cold chains start with 
the manufacturer in a developed country. From there, the vaccine is typically flown to a central 
store. This central store will house the vaccine for a t ime, after which it sends the vaccine to 
regional stores, then to district stores , and finally to health clinics . Transportation between 
locations can be via plane , car, or even foot. It is estimated that the total process can take 
anywhere from 12-18 months (Cheyne, 1989) . During this time the vaccines are housed in 
refrigerators, cold boxes, or simply put on ice. 
As manufacturers often send vaccines to remote areas of the world, the vaccines are 
exposed to harsh climates and many unforeseeable challenges. Hurricanes , wars, or natural 
disasters can delay shipments for extended periods of time. Power outages or lack of fuel often 
render electric cooling units useless (Arya, 2000) . Many t imes vaccines are lost in international 
flights , or central stores do not have room for them due to poor stock control (Cheyne, 1989). It 
is foreseen that global climate change will only add to the difficulties in maintaining the stability 
of vaccines (Arya, 2000). The logistics of the cold chain are often impractical in low resource 
settings, and the costs often become a major burden to developing countries (Wolfson et al., 
2007). 
The burden of the cold chain on vaccine programs accounts for $200-$300 million 
dollars each year (Das, 2004) . This alone can contribute to 80% of the vaccine program's cost in 
developing countries (Chen et al., 2011) . The money spent on simply transporting these vaccine 
could vaccinate an additional 10 million children (Das, 2004). Countries impacted the most by 
these costs are areas with harsher climates. Areas using kerosene powered coolers , can go 
through half a liter of kerosene a day just to maintain temperatu res (Cheyne, 1989) . 
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Exposure to increased temperatures causes denaturation of viral proteins. 
Conformational changes of membrane proteins can cause the vaccine to lose its potency 
decreasing its ability to elicit an immune response. These conformational changes can also 
cause the viral particles to aggregate, inactivating the vaccine (Zhang et al., 2012). The decrease 
in vaccine potency requires an increase in dosages which in turn adds to the cost of vaccines for 
developing countries (Chen et al., 2011). Zhang et al. (2012) estimates that failure of the cold 
chain results in the loss of almost half of all global vaccines. 
1.4 Use of Collagen as a Vaccine Stabilizer 
Having seen the insufficiencies of the cold chain, I have hypothesized that collagen could 
be used as a vaccine stabilizer thus eliminating the need for a cold chain. Collagen is a fibrous 
structure that is made up of three parallel polypeptide strands (Shoulders et al., 2009). Collagen 
is one of the most abundant structural proteins, and makes up one third of all total protein. It is 
found in tendons, ligaments, vessels, as well as the extracellular matrix. 
The polypeptide strands of collagen typically consist of 
three repeating sequences with glycine being every third 
amino acid. The first two amino acids can vary, but the 
sequence typically goes as follows: Xaa Yaa Gly (Shoulders et 
al., 2009) . Because of the abundance of glycine (Figure 2) 
each strand, known as the alpha chain, is tightly wrapped 
Figure 2: Structure of the amino 
acid Glycine 
Photo taken from: 
http ://www. mpbio .com/ product.php ?pid=O 
4808822&country=223 
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around itself. Three of these alpha chains 
.i 
Triple helix 1.4 nm form a helix (Figure 3} that is held 
T 
together by hydrogen bonding between 
Alpha chain Q 
the alpha carbon of Glycine and the 
Amino acid - oxygen of the carbonyl group on the X 
sequenoe - Gly - X - y - Gly - X - y - Gly - X - y -
Figure 3: Structure of collagen fiber starting with the amino acid of the repeating sequence. 
amino acid sequence, alpha chain, and finally the 
right handed triple helix. The triple helix is held This causes a collagen strand to form a 
together by hydrogen bonding between the Glycine 
and the X amino acid. 
Photo taken from: http://www .namrata .co/categ ory/chemistry-of-
protein s/speci alized-protein-collagen/ 
right handed triple helix composed of 
three left handed helical alpha strands, 
with two hydrogen bonds within each amino acid triplet (Shoulders et al., 2009; Ottani et al., 
2001}. 
In our experiment, collagen was used in the form of gelatin. Gelatin is denatured 
collagen that was isolated from porcine skin. As Gelatin contains collagen strands of varying 
lengths going in all directions, this causes a meshwork with micro pores hence becoming a gel 
(Olsen et al., 2003}. 
1.5 Structure of Influenza 
Influenza A/California/07 /2009 (HlNl} virus and Influenza A/NWS/33 (HlNl} virus were 
both used in our study. Influenza is an enveloped virus, meaning it is surrounded by a cell 
membrane. This cell membrane makes influenza easy to kill, as one can disrupt the membrane 
with ethanol or simple sanitizers . While this is convenient for sanitizing, it presents a difficulty 
in stabilizing an influenza vaccine, as it is so easily disrupted. Inside the cell membrane are 8 
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single stranded negative sense RNA segments that encode 11 different proteins (Kumru et al., 
2014). The virus is spherical in shape, and is typically 80-120 nm in diameter. 
There are three different types of influenza viruses: A, B, and C. Influenza A and Bare 
the types that are most associated with the annual or "seasonal" flu. These are further broken 
down into subcategories depending on the glycoproteins that are found on the outer cell 
membrane. Two of these membrane proteins were used in our assays to determine the vaccine 
potency. The two membrane proteins are: hemagglutinin, and neuraminidase. 
Hemagglutinin (HA) and 
neuraminidase (NA) are the structural 
Influenza 
Virus 
Anatomy 
proteins that often elicit an immune 
Lipid 
Envelope 
- Neuramlnldase 
(Slalldase) 
response in our bodies. These proteins 
are often variable with 18 discovered HA 
subtypes and 9 NA subtypes. Influenza 
utilizes mutational drift to constantly 
change these membrane proteins, 
making it necessary for us to get flu shots 
annually. A dramatic change in the 
Figure 4: Structure of Influenza HlNl. Virus is 
enveloped with 8 single stranded RNA molecules. 
Membrane proteins shown in blue are 
neuraminidase, and proteins shown in red are 
hemagglutinin. 
Photo taken from: 
http://micro .magnet.fsu.edu/cells/viruses/influenzavirus.html 
hemagglutinin antigen is less frequent; however, changes in this protein are often responsible 
for larger pandemics (Kumru et al., 2014). 
We classify the flu by using HxNx to specify which subtypes are found on the membrane. 
Example Influenza A H1N1 contains HA subtype 1 and NA subtype 1. Vaccines use inactivated 
14 
viruses with these membrane proteins intact in order to elicit an immune response (Pushko et 
al., 2005}. 
The membrane protein HA is a trimer composed of two 
different domains: HA1 and HA2 (Figure 5}. HA has a head, 
which binds to sialic acid found on receptors of the cells within 
the body. These cells then engulf the virus via endocytosis. 
Once inside the cell as an endosome, the virus utilizes a 
channel that lowers the pH of the endosome. The lowering of 
the pH causes a conformational change to occur in HA. After 
the conformational change, hemagglutinin unfolds on itself 
and exposes a part of the protein that bursts the endosome. 
This releases the viral RNA into the cell (Skehel et al., 2000). 
HA also binds to red blood cells causing them to agglutinate. 
This allows us to quantify the amount of HA in a sample, by 
simply mixing them with red blood cells. 
Putativo RBS 
Figure 5: Structure of 
hemagglutinin protein. Blue 
area represents HA2 domain 
and purple represents HA1 
domain. 
Photo taken from : 
http ://sbkb .org/update/research/virolo 
gy-a-bat-influenza-hemagglutinin 
Once the virus has replicated and undergone self-replication, the virus leaves the cell via 
exocytosis. Upon leaving the cell, however, the HA again binds to the host cell membrane and 
cannot leave. The enzyme neuraminidase (NA) frees the virus by cleaving the sialic acid on the 
cell membrane. This frees the virus allowing it to find another cell to infect. NA inhibitors, such 
as Oseltamivir (also known as Tamiflu), prevent the cleavage of sialic acid. While this does not 
stop the virus from initially infecting the cell, it prevents the virus from spreading to other cells. 
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1.6 Accelerated Stability Test 
As real time tests can take up to two years, we employed an accelerated stability test 
for our experiment. Accelerated stability tests assess the rate of change of vaccine potency over 
time by exposing the vaccine to increased temperatures that are above the normal storage 
conditions. While accelerated stability tests cannot be used to estimate real time, they provide 
important information regarding the stability and vaccine potency (WHO 2006). 
Methods and Materials 
2.1 Virus 
Influenza A/NWS/33 (HlNl) virus was used for our column chromatography tests . 
Influenza A/California/07 /2009 (HlNl) was the virus used for the accelerated time tests. Both 
viruses were provided by the Centers for Disease Control and Prevention in Atlanta, Georgia. 
The viruses were grown in MDCK cells after being infected in roller bottles. Infection was done 
by diluting the virus 1:1,100 in an infection media. Our flu infection medium consisted of: MEM 
(HyClone CAT# SH30024.02), 1 ml of Gentamycin (Sigma CAT# G1397), 10 U/ml of Trypsin 
(Sigma CAT# T6567), and 1 µg/ml EDTA (Sigma CAT# E9884). 
2.2 Virus Inactivation 
The virus was inactivated by Binary Ethylenimine (BEi). This was done by mixing 2-
Bromoethylamine hydrobromide (BEA) (Sigma) with 0.2 M of NaOH in sterile water and 
incubated for approximately one hour at 37°C +/-2° C. This results in a binary ethylenimine 
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(BEi) product. The BEi was then added to the virus at a ratio of one part of inactivating agent to 
nine parts of virus suspension. The final concentration of BEi was 10.0 mM. The virus-BEi 
mixture was then slowly stirred at 24°C +/-1 °c for 12 hours . We removed 20 ml samples every 
30 minutes for the first 7 hours, and then hourly until 12 hours. The BEi-Virus solution was 
neutralized by adding 1.0 M sodium thiosulfate, and the pH was brought to 7.2 by adding 1.0 M 
HCI. The inactivated virus was then filtered through a Pellicon XL Cassette {Biomax l00KDa Cat# 
PXBl00VS0) and put into 1 ml aliquots and stored at -80°C. 
2.3 Column Chromatography 
Inactivated influenza samples were passed through columns 
containing resins Capto Q and Capto 700, and then collected after 
buffer was added to the columns. The columns were initially washed 
with a phosphate buffer followed by 150 ml of the BEi inactivated 
virus. After the virus solution had been added to the columns they 
were washed again with the phosphate buffer. 100 ml increments 
of KCI containing phosphate buffers were added to each column. 
The columns were washed a third time and final eluates were 
collected. 
2.4 Bradford Protein Assay 
Figure 6: Columns used for 
column chromatography . 
Columns contain Capto Q or 
Capto700 resin. 
Photo taken in lab 
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After inactivated influenza samples were taken 
from the column, a Bradford Protein Assay was used to 
evaluate total protein concentration. The inactivated 
influenza samples were compared to a standard 
containing Bovine Serum Albumin that ranged from Oto 
2000 µg of protein. 
2.5 SDS Page 
Figure 7: Plate used for a Bradford 
Protein Assay. Samples were placed 
on the bottom 4 rows. Bovine 
Serum Albumin control was placed 
in the top right corner . 
Photo taken in lab 
Once protein concentrations were determined, selected samples were passed through a 
7.5% precast polyacrylamide gel. An electrical current of 200 V was applied for 10 minutes and 
then reduced to 150 V for 40 additional minutes. Total run time was 50 minutes. 
2.6 Gelatin 
Two different gelatins were used. The first was Gelatin from Porcine Skin (G9136-10 µg 
Type A lyophilized powdery-irradiated BioXtra Sigma). The second gelatin used was Porcine 
Skin Gelatin (CAT# GELP12-N-10 Lot# SX0018 Alpha Diagnostic Intl. Inc). 
2. 7 Sample Preparation 
Inactivated influenza samples were tested on four different variables : Viral protein 
concentration, temperature, time and gelatin concentration. Using an HA assay, the original 
viral protein concentration from our BEi inactivated stock was found to be 2.8 mg/ml. We used 
this stock to test protein concentrations at lmg/ml and 0.3 mg/ml. Our gelatin concentrations 
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were tested as both percent by total protein concentration, as well as percent by total volume . 
Our gelatin percentages were 0.3%, 1%, 3%, and 10%. Temperature variables were 45°C, 52°C, 
and 60°C. Each sample was also made for the following time intervals: 1 min , 5 min , 10 min, 20 
min, 40 min, 60 min, 120 min, 240 min, 300 min and 360 min. Inactivated influenza samples 
were prepared to a volume of 500 µI per sample. Two controls were utilized: the first was BEi-
inactivated virus with no gelatin, and the other was BEi-inactivated virus with 3% of albumin by 
protein concentration/volume . 
When testing the gelatin percent by total protein, we used the Type A lyophilized 
powder (y-irradiated BioXtra) from Sigma. The gelatin stock was prepared at 1 mg/ml by mixing 
10 mg of the lyophilized gelatin with 10 ml of phosphate buffered solution (PBS). Table 1 shows 
the volumes that were used to make the samples at a total viral protein concentration of 1.0 
mg/ml. Table 2 shows the volumes that were used to make samples at a total viral protein 
concentration of 0.3 mg/ml. 
It was found that the gelatin concentrations were not sufficiently high, so inactivated 
influenza samples with gelatin by percent of total volume were made. Porcine Skin Gelatin 
(CAT# GELP12-N-10 Lot# SX0018 Alpha Diagnostic Intl. Inc) was diluted to 200 mg/ml by mixing 
1 gram of gelatin with 5 ml of PBS. As it has previously been demonstrated that optimal viral 
protein is at 0.3 mg/ml , samples of gelatin by percent of total volume were made with only 0.3 
mg/ml of viral protein. Table 3 shows the volumes that were used to make these samples . 
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Table 1: Inactivated influenza sample volume preparation of 1.0 mg/ml viral protein 
concentration with gelatin by percent of total protein concentration 
Gelatin by% of total Amount of BEi- Amount of Gelatin Inactivated Virus Amount of PBS protein 
added from stock added (in µI) 
concentration (in µI) 
10% 167 193 
3% 167 286 
1% 167 317 
0.3% 167 328 
0%* 167 333 
Control 
3% Albumin* 167 286 
Control 
* Following samples contained NO gelatin but were used as controls 
** 47 µI added were of Albumin NOT gelatin 
added from stock 
(in µI) 
140 
47 
16 
5 
0 
47* * of Albumin 
Table 2: Inactivated influenza sample volume preparation of 0.3 mg/ml viral protein 
concentration with gelatin by percent of total protein concentration 
Gelatin by % of total Amount of BEi- Amount of Gelatin 
Inactivated Virus Amount of PBS protein 
added from stock added (in µI) added from stock 
concentration (in µI) (in µI) 
10% 55 305 140 
3% 55 398 47 
1% 55 429 16 
0.3% 55 440 5 
0%* 55 445 0 
Control 
3% Albumin * 55 398 47 of Albumin ** 
Control 
* Following samples contained NO gelatin but were used as controls 
** 47 µI added were of Albumin NOT gelatin 
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Table 3: Inactivated influenza sample volume preparation of 0.3 mg/ml viral protein 
concentration with gelatin by percent of total volume 
Amount of BEi-
Amount of Gelatin Gelatin by % of total Inactivated Virus Amount of PBS 
added from 200 
volume added from stock added (in µI) 
mg/ml stock (in µI) (in µI) 
10% {100 mg/ml) 55 195 250 
3% (30 mg/ml) 55 362 83 
1% (10 mg/ml) 55 420 25 
0%* 
55 455 0 Control 
3% Albumin * 
55 83 of Albumin ** Control 362 
* Following samples contained NO gelatin but were used as controls 
** 83 µI added were of Albumin NOT gelatin 
2.8 Accelerated Stability Test 
The accelerated stability test was performed by placing inactivated influenza samples in 
water baths and removing them after a set period of time. Water baths were set at 45°C, 52°C 
and 60°C. Samples were removed from the water baths at the following intervals : 1 min, 5 min , 
10 min, 20 min, 40 min, 60 min , 120 min, 240 min , 300 min and 360 min. Once samples were 
collected, they were placed immediately in a -80°C freezer until further tested. 
2.9 Hemagglutinin (HA) Assay 
50 µI of PBS was added to each well of a round bottom 96-well micro-titer plate. In the 
first row 50 µI of the test sample was added , and serially diluted by transferring 50 µI from the 
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previous well to the successive well and so on. 50 µI of a 
0.5% turkey red blood cell (RBC) suspension was added to 
each well on the plate. Cell and virus controls were added 
to the same plate. After viral sample addition, plates were 
incubated at room temperature. Wells that contained viral 
proteins, caused the red blood cells to form a lattice work 
and stay in suspension. Wells without any viral proteins 
Figure 8: Microtiter plate on 
which hemagglutinin assay was 
performed. Wells with red dots 
show no viral proteins, while 
wells with no dots indicate 
hemagglutination has occurred. 
formed "buttons" at the bottom of the well where the red Photo taken in lab 
blood cells clumped due to gravity. Titers were recorded after 35 minutes. HA units were 
expressed as the reciprocal of the maximum dilution of virus that resulted in complete 
agglutination. 
2.10 Neuraminidase {NA) Assay 
Viral NA activity was assessed using a commercially available kit (NA-Star"lnfluenza 
Neuraminidase Inhibitor Resistance Detection Kit, Applied Biosystems, Foster City, CA} in 96-
well solid white microplates. Inactivated influenza samples were serially diluted using a 1:2 
dilution with the NA-Star Assay Buffer. NA-Star Substrate was then prepared by making a 
1:1000 dilution in the NA-Star Assay Buffer. 10 µI of the diluted substrate were then added to 
each of the wells. The plate was incubated at 37° C for 20 minutes. After incubation the NA 
activity was evaluated using a Centro LB 960 luminometer (Berthold Technologies) for 0.5 sec 
immediately after addition of NA-Star" accelerator solution . NA activity was determined by 
plotting percent chemiluminescent counts versus log10 of the NA dilutions. 
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Results 
3.1 Hemagglutinin (HA) Assay for Column Chromatography 
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Figure 9: Graph shows the HA value versus the Elution Buffer in Molarity. The blue line 
represents samples that were collected from the column containing the Capto Q resin on the 
28th of September 2013. The orange line represents samples collected on the 2nd of November 
2013 . 
Figure 9 shows HA concentrations from samples taken from the column containing the 
Capto Q resin. There was a peak of hemagglutinin in the 0.2M eluates collected on the 28 of 
September 2013. 
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Figure 10: Graph shows the HA value versus the Elution Buffer in Molarity. The blue line 
represents samples that were collected from the column containing the Capto 700 resin on the 
28th of September 2013. The orange line represents samples collected on the 2nd of November 
2013. 
Figure 10 shows the eluates collected from the column containing the Capto 700 resin. 
The graph displays the concentration of the viral hemagglutinin protein. The data collected 
from the 28 of September 2013 suggests that the viral protein did not bind to the column, but 
rather flowed through the column . 
3.1 Bradford Protein Assay for Column Chromatography 
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Figure 11 comes from the Bradford Protein Assay which shows the total protein 
concentration present in the eluates collected. This assay showed a peak in protein 
concentration . When comparing this graph with figure 9, one can see that the protein peak 
corresponds to the hemagglutinin peak concentration. 
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Figure 11: Graph shows the total protein concentration from each of the eluates collected from 
the column. The blue line represents samples that were collected from the column containing the 
Capto Q resin on the 28th of September 2013. The orange line represents samples that were 
collected on the 2nd of November 2013. 
25 
18 
E 16 
....... 
gf 14 
C: 12 
0 
·,.::; 10 
('Cl 
.::; 8 
C: 
Q) 6 
I.I 
C: 4 0 
u 2 
C: 
Q) 0 
0 
... 
c.. 
('Cl 
~ 
Total Protein Content After Capto 700 
1st Phos Buf Elut ion Elut ion 
Samp le 1st w ash Buf . lM Buf .2M 
Elut ion Elution Eluti on Phos Buf 
Buf .3M Buf .4M Buf .SM 2nd Wash 
Eluates collecte d fro m colum n 
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Capto 700 resin on the 28th of September 2013. The orange line represents samples that were 
collected on the 2nd of November 2013. 
Figure 12 shows the total protein concentration present in the eluates collected from 
the Capto 700 column . This graph indicates a similar peak of total protein concentration on 
both occasions in which the column was run. There does not seem to be a correlation between 
the total protein concentration and the hemagglutinin content (Figure 10) from the eluates 
collected from the Capto 700 resin. 
3.3 SOS Page for Column Chromatography 
Figure 13 is of an SDS gel that shows a 
single band of protein that was identified at 
approximately 60kDa. The fact that the band was 
identified after the pt phosphate buffer wash 
Phm 8uf But 8uf But Buf a.t Bui 
1stWo,h .1 M .2M .3M 
Figure 13: SOS Page of eluates collected 
from columns. A faint band can be seen 
coming from the ist phosphate buffer wash 
at around 60 KDa. 
Photo taken in lab 
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suggests that either the viral protein did not stick to the column, or that the protein visible on 
the gel was due to a contaminant (possibly bovine serum albumin.) As only one band of 
protein was visible, a more sensitive dye will be needed to detect lower concentrations of 
protein . 
3.4 Hemagglutinin (HA) Assay for Accelerated Stability Test 
Figures 14-16 show the HA results from the accelerated stability test with a viral protein 
concentration of 1.0 mg/ml. Figure 14 shows samples that were placed in a water bath at 60°C. 
The results show, that the temperature was too high, denaturing the viral proteins at all gelatin 
concentrations. 
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Figure 14: Graph shows the HA concentrations of samples taken from 60°C 
water bath at different intervals . As shown in the graph, all viral proteins were 
denatured after 10 minutes indicating that our water bath temperature was 
too high . 
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Figure 15 shows the HA concentrations of samples taken from a 45°C water bath at 
different time intervals. This shows that there no difference of HA was observed between the 
samples, suggesting that our water bath temperature was too low. 
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Figure 15: Graph shows the HA Concentrations of samples taken from 45°C water bath at 
different intervals. 
Figure 16 shows the HA concentrations of samples taken from a 52°C water bath at 
different time intervals. The graph shows a drop in viral protein concentration after a set period 
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Figure 16: Graph shows the HA concentrations of samples taken from 52°C 
water bath at different intervals. There is a drop in hemagglutinin 
concentration around 60 minutes indicating S2°C as an optimal temperature 
for accelerated stability test . 
of time, indicating that 52°C is optimal for our accelerated stability test. The graph also shows 
that no difference in stability was observed between the different gelatin concentrations . 
After looking at our results for the accelerated stability tests with a protein 
concentration of 1.0 mg/ml, we repeated our accelerated stability tests with a protein 
concentration of 0.3 mg/ml. Figure 17 shows the HA concentrations of those samples. While we 
saw some differences in our inactivated influenza samples, there was no evidence that gelatin 
extended the stability of the vaccine. The graph also show that there was not a drop in 
hemagglutinin in our control , suggesting that the temperature was too low to cause 
denaturation for the time intervals set. 
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Figure 17: Graph shows the HA concentrations of 0.3 mg/ml viral protein 
samples taken from a 45°C water bath. While there is variance in the 
samples, there is not a difference between the values to suggest that any 
sample had an increase in stability. 
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Figure 18: HA concentrations of 0.3mg/ml viral protein samples taken from a 
52° C water bath. Despite variance between HA values in samples during the 
first 100 minutes, no difference in viral protein stability can be seen. 
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As we did not see a decrease in HA from the 45° C water bath, we tested the 0.3 mg/ml 
viral protein samples at 52 °c. Once again there was no significant difference between the 
inactivated influenza virus samples (Figure 18) to say that the gelatin had an effect on the 
stability of the viral proteins. 
As no stabilizing effect could be seen from the gelatin, we hypothesized that the gelatin 
concentrations were too low . We increased our gelatin by using a percent by total volume. As 
we had found that 52°C was the optimal temperature for our tests, we performed an 
accelerated stability test with gelatin by percent of total volume at 52°C. As figure 19 shows 
there was yet again no difference between our samples and the control. 
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Figure 19: HA concentrations of samples containing a 0.3 mg/ml viral protein 
concentration . The gelatin samples are 10%, 3%, 1%, and 0% by total volume . 
Samples were taken from a 52° C water bath. 
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As no differences in vaccine stability could be seen between our samples and our 
control, we hypothesized that the gelatin might be interfering with the red blood cells used in 
our hemagglutination assay. To test this, we took samples of 0.3mg/ml viral protein that were 
not placed in water baths and performed an HA on them. As none of the inactivated influenza 
samples had been exposed to elevated temperatures, the estimated HA was around 258. The 
gelatin was measured as percent by total volume using 0.5%, 1%, 2%, 3%, and 4%. As figure 20 
shows, our hypothesis was confirmed that the gelatin was interacting with the assay and 
interfering with our results. 
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Figure 20: HA concentrations of samples containing a 0.3 mg/ml viral 
protein concentration. None of the samples were exposed to elevated 
temperatures, and were expected to have an HA value of 258. As the graph 
shows. the gelatin seems to affect the HA values of the assav. 
3.5 Neuraminidase {NA) Assay for Accelerated Stability Test 
As gelatin interfered with the results of our HA assay, a NA assay was performed on samples 
containing a 0.3 mg/ml viral protein concentration. Inactivated influenza samples contained 1%, 
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3%, and 10% gelatin by total volume and were placed in a water bath at 52°C. NA activity was 
determined by plotting percent chemiluminescent counts versus log10 of the NA dilutions. 
Graphs representing each time interval inactivated influenza vaccine was removed from the 
water bath. Figures 21-28 show the results of the neuraminidase activity . 
Figures 21-28 show significant differences in chemiluminescence between gelatin samples and 
the control were seen within 10 minutes of exposure to elevated temperatures. The 3% gelatin 
sample has around a 10,000 fold increase in neuraminidase activity than the control after 240 
minutes. 
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Figure 21: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to S2°C 
water bath for 1 minute. Graph shows chemiluminescence vs 
NA dilution 
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Figure 22: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to S2°C 
water bath for 5 minutes. Graph shows chemiluminescence 
vs NA dilution 
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Figure 23: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to S2°C water 
bath for 10 minutes. Graph shows chemiluminescence vs NA 
dilution 
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Figure 24: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to 52°C 
water bath for 20 minutes. Graph shows 
chemiluminescence vs NA dilution 
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Figure 25: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to S2°C 
water bath for 40 minutes. Graph shows chemiluminescence 
VS NA dilution 
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Figure 26: Neuraminidase activity of samples containing 0.3 mg/ml 
viral protein concentration after exposure to S2°C water bath for 
60 minutes . Graph shows chemiluminescence vs NA dilution 
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Figure 27: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to S2°C 
water bath for 120 minutes. Graph shows chemiluminescence 
vs NA dilution 
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Figure 28: Neuraminidase activity of samples containing 0.3 
mg/ml viral protein concentration after exposure to s2°c water 
bath for 240 minutes. Graph shows chemiluminescence vs NA 
dilution 
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Conclusions 
4.1 Column Chromatography 
The results from our column chromatography study showed that a peak prote in 
concentration appeared to correlate with peak HA content in both columns (Figures 11 and 12). 
This suggests that little protein purification has occurred. A band of 60 KDa protein was 
identified by the SDS-PAGE from the l51 phosphate buffer wash (figure 13). Because the HA 
assay identifies viral proteins in later eluates (Figure 9), the datum suggests that the band of 
protein is a contaminant and not the desired viral protein . It is hypothesized that the sensitivity 
of the Simply Blue dye used was too low . A more sensitive dye could be used, such as a silver 
stain, to ident ify any remaining proteins in the sample . 
As we were not able to identify our protein of interest with the column 
chromatography , our results for the column chromatography still remains inconclusive . Such 
purification is theoretically possible , but more tests are required to achieve this. 
4.2 Hemagglutinin (HA) Assay for Accelerated Stability Test 
As shown in figures 14-20, there was no significant difference in the HA activity between 
the gelatin samples and the control. It was confirmed that gelatin was interfering with the HA 
assay by performing an HA on samples that had not been exposed to elevated temperatures 
(Figure 20). Since none of the sample had been exposed to elevated temperatures similar HA 
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values were expected. The results show that only the control, albumin, and 0.5% gelatin 
samples had recordable HA values. 
Since the exact mechanism for the gelatin interference is unknown, I hypothesize that 
the gelatin could be causing some form of aggregation with the blood cells. It is known that 
collagen is a main stimulant for platelet aggregation. As the body is full of redundancies and 
multiple pathways, I hypothesize that the collagen could have caused agglutination in the 
erythrocytes th at were used. 
4.3 Neuraminidase (NA) Assay for Accelerated Stability Test 
Our results from figures 21-28 show that viral protein stability was achieved by the use 
of gelatin. The 0.3% gelatin sample was shown to have approximately 10,000 fold increase in 
NA activity. Such increased activity suggests that gelatin could be used as an effective vaccine 
stabilizer. 
Discussion 
The cold chain has been the largest obstacle in distributing vaccines around the world. 
Because vaccines must be kept at low temperatures, many areas of the world struggle to keep 
the vaccine potency throughout the transportation process . If a vaccine stabilizer was used, 
vaccines could be distributed at room temperature without losing vaccine potency . Our results 
have shown that gelatin could be used as an effective vaccine stabilizer for the influenza HlNl 
BEi inactivated virus. 
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The exact stabilizing mechanism of gelatin is still unknown. Based on the findings two 
hypothesis can be suggested . The first has to do with the structure of gelatin. As gelatin is 
simply denatured collagen, there is a meshwork of tiny pores that are formed from the 
different lengths of collagen strands. This could possibly form small nanoscale environments 
that are optimal for the viral particles . Such stabilization has been seen in the application of silk 
as a stabilizer (Zhang et al., 2012). 
Another hypothesis for gelatin's stabilizing ability, could be from binding of the gelatin 
to the virus. According to Liska et al. (2007) gelatin provides non covalent binding to virus 
particles that is non-specific. It is believed that this binding could enhance the stability of the 
viral particles. As we can only hypothesize the stabilizing mechanisms of collagen, more 
research is required . 
While it has been shown that gelatin can increase the stability of a vaccine, it should be 
noted that one cannot inject a patient with the gelatin still inside. Many studies have shown 
that endogenous gelatin can cause serious allergic responses (Sakaguchi et al., 2000). Because 
of this danger, we have collaborated with our partner Dr. Michael Seungju at the University of 
Utah. Dr. Seungju has developed a peptide that binds to gelatin. With this peptide, we could 
use gelatin as a stabilizer and then extract it from the vaccine after successful transportation. 
This could revolutionize the way vaccines are shipped around the world. 
The cold chain is one of the most difficult problems we face in vaccine distribution 
today. 80% of funds for vaccine production is spent on the effective transportation of the 
vaccines. With the use of gelatin as a vaccine stabilizer, we can eliminate the cold chain 
40 
altogether. This could not only increase the accessibility of vaccines across the world, but has 
the potential to save millions of lives each year. 
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Being a biology major, my classes have been very science oriented . There did not seem 
to be very much overlap in the humanities programs . My involvement with UNICEF, however, has made 
me very interested in areas such as global health . I found it difficult at times to combine my interests in 
UNICEF with my biology degree . It felt as if they were two separate aspects of my life that were 
completely polar from each other. 
My capstone project was an opportunity to be able to bridge all of my interests during my 
college career into a single reflective project . Working at the Institute for Antiviral Research, I was 
introduced to Dr. Bart Tarbet . Dr. Tarbet has worked with vaccine manufacturing for a number of years, 
as well as BARDA. After talking with him, I discovered that we shared a common interest in global 
health . I found this as an opportunity to apply my interests from UNICEF with projects that I was already 
working on in the lab. 
As I worked with Dr. Tarbet for over two years, I was able to learn a vast amount of assays and 
procedures . I started off basic, learning how to do something as simple as culturing cells and aseptic 
technique . Towards the end of my college career, I was able to do all of my own viral dilutions and 
sample preparations . 
Of all of the lessons that I have learned from my project, the greatest is probably persistence. 
Many times our tests would fail and we would not get the data we wanted . I constantly had to go back 
and evaluate what I did, and find ways to improve . There were many 12 hour Saturdays spent in the lab, 
only to find that our results did not work. This was frustrating at times, but it taught me that there is no 
such thing as a "failed" experiment. You take your results, and learn what you can do better. 
There was a time during my undergraduate career, that I had to take a hiatus form my research 
in order to study for my MCAT. As I was applying for medical school, I was finding it difficult to spend the 
amount of time I needed to in the lab. This hiatus was strenuous on my project, and it is reflective on 
our column chromatography data. As the project required more time, we were not able to get the 
results we wanted. Once I finished my MCAT I had intended on returning to the column chromatography 
project but we were presented with a more promising alternative; vaccine stabilization. 
While I found the vaccine stability project to be very exciting, it also came with many failed 
results . We had read a number of different journals that had said vaccine stability could be achieved 
through gelatin stabilization, yet we were not able to reproduce these results . I found myself constantly 
looking at our variables and seeing what we needed to change. This was anything from our temperature 
to our viral protein concentration. 
My proudest moment, however, came from looking at another "failed" run and realizing that 
was not due to our error. After looking at the results closely, it became clear to me that the gelatin had 
to have been interfering with our assay. We made a hypothesis, and ran a tests to see if we were 
correct . One of the most gratifying feelings I have ever felt, was getting our results and seeing that it 
supported our hypothesis. While I have applied the scientific method many times in my college career, 
this was the first time that it was not laid out for us in a lab manual. I felt like I was a pioneer in a new 
field, or an explorer discovering something for the first time. 
After taking our results, we were able to evaluate different membrane protein found on the 
virus. At this point, it was like something just clicked. Our results started coming back beautiful. I felt 
giddy to finally, after two years, start getting results that were working. To anyone else, it might just 
look like lines on a graph, but to me it is a reflection of years of dedication and hard work. 
My honor's capstone thesis has been one of the most rewarding achievements I have done in 
my entire undergraduate career. This project has pushed me farther than any other class I have taken. I 
have spent countless hours in a lab and reading journals, but it has been worth every second of it. 
Looking at the finished project, I am proud of how difficult it was. 
If I could give advice to anyone starting a thesis, I would say this: Find something you are 
passionate about. The amount of time spent on this project was far more than a three credit class, but 
because I was invested in the results it never felt like a burden. By taking pride in your project , it will 
push you to do more than what is merely required of you. By thinking about your thesis early on in your 
undergraduate career, you can identify a project that will reflect not only what you did during your time 
at USU, but who you became as a person. 
I am grateful to have had a mentor that was able to council me and help me to do more than I 
thought I ever could . Dr. Tarbet pushed me to strive for perfection. While at times I thought he was 
being nitpicky on little things, I have realized that he was helping me to be the best that I could be. I am 
also grateful for all of the faculty that have worked with me on my committee . I felt that the faculty on 
my project genuinely cared about me and my future plans. I do not think I would have gotten to know 
them at this level if it had not been for my project. This has project has truly been a capstone that 
served as an emotional finale for my time here at Utah State University. Thank you for the opportunity! 
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semesters in Human Anatomy, Human Dissection, as well as Advanced Human Physiology. 
Jorgen has also served as a camp facilitator for the Hugh O' Brian Youth (HOBY) Leadership 
camps. From 2012-2014 Jorgen worked as a volunteer in the Logan regional emergency room. 
From 2013 -2015 Jorgen worked as the lead animal technician for the Institute for 
Antiviral Research at Utah State University . During that time he has assisted in a number of 
different in vivo studies, as well as in vitro . During his time with the Institute for Antiviral 
Research, Jorgen started working with Dr. Bart Tarbet with research projects that he felt related 
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months leading up to his thesis. 
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